• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Adv Res . Palmitoylated COX-2Cys555 reprogramed mitochondrial metabolism in pyroptotic inflammatory injury in patients with post-acute COVID-19 s

tetano

Editor, Senior Moderator
J Adv Res


. 2025 May 9:S2090-1232(25)00299-1.
doi: 10.1016/j.jare.2025.05.005. Online ahead of print. Palmitoylated COX-2[SUP]Cys555[/SUP] reprogramed mitochondrial metabolism in pyroptotic inflammatory injury in patients with post-acute COVID-19 syndrome

Jia-Shen Wu[SUP] 1 [/SUP], Chi-Yu Xu[SUP] 2 [/SUP], Su-Min Mo[SUP] 3 [/SUP], Xin-Mou Wu[SUP] 4 [/SUP], Ze-Bang Du[SUP] 5 [/SUP], Lin Che[SUP] 6 [/SUP], Yi-Ling Zhang[SUP] 7 [/SUP], Kai-Li Yang[SUP] 8 [/SUP], Ting-Dong Li[SUP] 9 [/SUP], Sheng-Xiang Ge[SUP] 10 [/SUP], Tian-Ying Zhang[SUP] 11 [/SUP], Zhong-Ning Lin[SUP] 12 [/SUP], Yu-Chun Lin[SUP] 13 [/SUP]



Affiliations
Abstract

Introduction: The complex interplay between protein palmitoylation, mitochondrial dynamics, and inflammatory responses plays a pivotal role in respiratory diseases. One significant features of post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) is the occurrence of a storm of inflammatory cytokines related to the NOD-like receptor protein 3 (NLRP3). However, the specific mechanisms via which palmitoylation affects mitochondrial function and its impact on the NLRP3 inflammasome under pathological respiratory conditions remain to be elucidated.
Objective: This study aimed to investigate how protein palmitoylation influences the inflammatory responses and mitochondrial dynamics in respiratory diseases, such as those induced by the SARS-CoV-2 spike S protein in PACS, thereby providing a therapeutic target for inflammatory lung injury.
Methods: In vivo experiments were conducted using AdV5-pADM-CMV-COVID-19-S (AdV5-S) nasal drip-treated C57BL/6 mice to assess NLRP3 inflammasome activation and inflammatory response. In vitro experiments were performed using pCMV-S-transfected human lung epithelial BEAS-2B cells to analyze the effects of DHHC5-mediated palmitoylation of cyclooxygenase-2 (COX-2) at cysteine 555 (COX-2[SUP]Cys555[/SUP]) on mitochondrial metabolism and NLRP3 inflammasome activation.
Results: Palmitoylation of COX-2[SUP]Cys555[/SUP] enhanced its interaction with hexokinase 2 (HK2) to regulate mitochondrial metabolic reprogramming, leading to NLRP3 inflammasome activation and pyroptosis. Pharmacological and genetic suppression of palmitoylation diminished the mitochondrial localization of palmitoylated COX-2 and its interaction with HK2, thereby reducing mitochondrial metabolic reprogramming. Furthermore, genetic intervention targeting DHHC5 (shDhhc5) alleviated NLRP3 activation and pyroptosis, mitigating the chronic inflammatory damage associated with PACS.
Conclusion: This study highlights the regulatory role of COX-2[SUP]Cys555[/SUP] palmitoylation in mitochondrial metabolism and lung inflammatory injury, and suggests potential therapeutic targets to combat respiratory pathogenesis linked to palmitoylated COX-2.

Keywords: COX-2 palmitoylation; Lung inflammatory injury; Mitochondrial metabolic reprogramming; NLRP3 inflammasome activation; Post-acute COVID-19 syndrome (PACS); SARS-CoV-2 spike protein.

 
Back
Top Bottom